Literature DB >> 6464059

Failure of flunarizine to improve cerebral blood flow or neurologic recovery in a canine model of complete cerebral ischemia.

L A Newberg, P A Steen, J H Milde, J D Michenfelder.   

Abstract

Ten minutes of cerebral ischemia was produced in 12 dogs by temporary ligation of the venae cavae and aorta. After reperfusion the dogs received the calcium entry blocker, flunarizine, 6 micrograms/kg infused over a ten minute period. Cerebral blood flow (CBF) and metabolism (CMRO2) were measured pre-ischemia and for 2 h post-ischemia in 6 dogs. At the end of the study brain biopsies were analyzed for cerebral metabolites. Neurologic recovery was evaluated for up to 48 h post-ischemia in an additional 6 dogs. The results of each study were compared to those previously obtained in untreated animals. The cerebral blood flows (when expressed as a percent of the pre-ischemic control value) of the flunarizine-treated and untreated groups were similar throughout the post-ischemic period. Following an initial hyperemia, the CBF fell to significantly less than the pre-ischemic control values, and remained approximately 26% of control during the final 90 min in both groups. The CMRO2 was also the same for both groups. Cerebral metabolites were similar although abnormal in both groups. Flunarizine produced pulmonary edema in 5 of 6 dogs studied for neurologic recovery. Four of these dogs died within 12 h and another dog demonstrated severe neurologic damage. None of the untreated dogs developed pulmonary edema, but 6 of 7 dogs evidenced severe neurologic damage or were dead at 48 h. Thus, flunarizine failed to improve either cerebral blood flow or neurologic outcome when given after complete cerebral ischemia in the dog. A cardiodepressive effect of flunarizine might have contributed to the poor neurologic outcome.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6464059     DOI: 10.1161/01.str.15.4.666

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  13 in total

Review 1.  The physiology of cardiopulmonary resuscitation.

Authors:  M C Rogers
Journal:  Intensive Care Med       Date:  1989       Impact factor: 17.440

2.  Effect of nicardipine on somatosensory evoked potentials in patients with acute cerebral infarction.

Authors:  L P Yao; D Y Ding
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-10       Impact factor: 10.154

3.  Cross-clamping of the thoracic aorta. Influence of aortic shunts, laminectomy, papaverine, calcium channel blocker, allopurinol, and superoxide dismutase on spinal cord blood flow and paraplegia in baboons.

Authors:  L G Svensson; C M Von Ritter; H T Groeneveld; E S Rickards; S J Hunter; M F Robinson; R A Hinder
Journal:  Ann Surg       Date:  1986-07       Impact factor: 12.969

4.  Prevention and treatment of brain ischaemia.

Authors:  C J Hinds
Journal:  Br Med J (Clin Res Ed)       Date:  1985-09-21

Review 5.  Anesthesia and monitoring for carotid endarterectomy.

Authors:  G J Theisen; B L Grundy
Journal:  Bull N Y Acad Med       Date:  1987-10

Review 6.  The physiology of cerebral blood flow during cardiopulmonary resuscitation.

Authors:  I D Berkowitz; M C Rogers
Journal:  Can J Anaesth       Date:  1988-05       Impact factor: 5.063

Review 7.  Brain protection: physiological and pharmacological considerations. Part II: The pharmacology of brain protection.

Authors:  R Hall; J Murdoch
Journal:  Can J Anaesth       Date:  1990-10       Impact factor: 5.063

8.  Effects of emopamil on postischemic blood flow and neuronal damage in rat brain.

Authors:  G W Bielenberg; D Sauer; J Nuglisch; T Beck; C Rossberg; H D Mennel; J Krieglstein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989 Jan-Feb       Impact factor: 3.000

9.  An in vitro model of anoxic-induced damage in mouse brain.

Authors:  G E Gibson; V Mykytyn
Journal:  Neurochem Res       Date:  1988-01       Impact factor: 3.996

Review 10.  Calcium channel antagonists. Part V: Second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.